Article
Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
BMC cancer - 29 Jul 2020
Shen Chiung-Chyi, Cheng Wen-Yu, Lee Chung-Hsin, Dai Xue-Jun, Chiao Ming-Tsang, Liang Yea-Jiuen, Hsieh Wan-Yu, Mao Tsuo-Fei, Lin Guo-Shi, Chen Shou-Ren, Liu Bai-Shuan, Chen Jun-Peng
Abstract excerpt
BACKGROUND: It has previously been shown that bevacizumab, when added to chemotherapy, improved overall survival in several cancers. In glioblastoma multiforme (GBM), bevacizumab increased progression-free survival and it is widely used for tumor recurrence, though it has failed to improve overall survival (OS) in controlled trials. However, an effective biomarker for predicting the prognosis of bevacizumab...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
